Presentation Title: Evaluating the Effect of Prebiotics on the Gut Microbiome Profile and β-cell Function in Newly-Diagnosed Type 1 Diabetes
Author Name(s): Heba Ismail, MB BCh; Carmella Evans-Molina, MD, PhD; Linda A DiMeglio, MD, MPH
Author Department and School Affiliation: Indiana University Purdue University Indianapolis Department of Pediatrics
Abstract: Emerging data suggest that differences in intestinal microbiota might be critically involved both in autoimmunity and in glucose homeostasis in people with type 1 diabetes (T1D). The prebiotic high amylose maize starch (HAMS) alters the gut microbiome profile and metabolites positively by increasing production of beneficial short chain fatty acids (SCFAs) that have significant anti-inflammatory effects. It also improves glycemia, insulin sensitivity and secretion in healthy non-diabetic adults. Further, an acetylated and butyrylated form of HAMS (HAMS-AB) that increases beneficial SCFA production, namely acetate and butyrate, has been safe and effective in disease prevention in mouse T1D models. The objective of the proposed study is to assess the effect of administering HAMS-AB, on the gut microbiome profile, SCFA production, glycemia, β-cell function as well as markers of autoimmunity in humans with T1D.
This is a pilot randomized controlled cross-over trial of HAMS-AB in 12 youth with newly-diagnosed T1D. We have thus far enrolled 2 participants and enrolling is ongoing to collect and analyze the samples. We expect that the use of HAMS-AB in newly diagnosed T1D youth will restore the gut microbiome balance (thus increasing SCFA levels), glycemia, β-cell function and reduce markers of autoimmunity in T1D youth.